Figure 4.
A: Overall survival In the COAT (Cryptococcal Optimal ART Timing) trial comparing early and delayed antiretroviral therapy (ART) In patients with cryptococcal meningitis. Adapted from Boulware, N Eng J Med, 2014.10 B and C: Trial in patients with cryptococcal meningitis showing reduced risk of neurologic deterioration in patients with culture-negative results and reduced risk of immune reconstitution inflammatory syndrome (IRIS) in patients with sterile cerebrospinal fluid at the start of ART. Adapted from Chang et al.11